The strong Q2 beat and potential guidance raise signal accelerating commercial adoption of Amtagvi. Traders should watch for the formal guidance update in Q3 and upcoming ESMO data presentations (Oct 23-27) for lifileucel in sarcomas and frontline melanoma, which could be additional catalysts.
Price Chart
Executive Summary
Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi revenue of ~$91M. Gross margin improved to 56%, and the net loss narrowed to -$0.11/share from -$0.33/share YoY. The company is reviewing its FY26 revenue guidance of $350M-$370M for a potential raise, while advancing its pipeline with FDA Fast Track Designation for lifileucel in soft tissue sarcomas.
Key Financial Metrics
Key Facts
- Total product revenue of ~$99.3M, up 66% YoY from ~$59.95M in Q2 2025.
- U.S. Amtagvi revenue reached ~$91M, up 40% from Q4 2025.
- Gross margin improved to 56% from 41% in Q1 2026.
- Net loss per share narrowed to -$0.11 from -$0.33 YoY, beating consensus of -$0.13.
- Company reviewing FY26 revenue guidance of $350M-$370M for a potential raise.
- FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS and DDLPS).
- Cash position of ~$304M expected to fund operations into 2H28.
Financial Impact
Record quarterly revenue of $99.3M, 66% YoY growth; net loss narrowed by $64.3M YoY to $47.3M.
Risk Factors
- Revenue growth dependent on continued Amtagvi adoption and ATC network expansion.
- Company remains unprofitable with operating losses; path to profitability uncertain.
- Clinical pipeline risks: trial enrollment, regulatory approvals, and competition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091619 |
| Document: tm2622322d1_8k.htm | 0001104659-26-091619 |
| Document: 0001104659-26-091619-index-headers.html | 0001104659-26-091619 |
| Document: 0001104659-26-091619-index.html | 0001104659-26-091619 |
| Document: 0001104659-26-091619.txt | 0001104659-26-091619 |
| 8-K Data (Synthetic) | 0001104659-26-091619 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.24 (+76.67%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.24 (+124.61%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.24 (+129.31%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.24 (−205.58%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.24 (+230.39%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.24 (+259.60%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.24 (+247.32%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.24 (+330.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access